CEO Jeffrey Simmons was paid $14,925,756 in fiscal year 2025, ↑ up 0.6% from fiscal year 2024, the 44th percentile of its disclosed peer group (SEC filing 0001739104-26-000016 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$14,925,756 ↑ Jeffrey Simmons total, FY2025 | 44th CEO pay percentile vs peers | 181:1 CEO-to-median pay ratio | 82% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ELAN's next annual pay disclosure, estimated April 20, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Simmons | $1,200,000 | $0 | $9,000,000 | $3,000,004 | $1,700,400 | $0 | $25,352 | $14,925,756 |
| President and CEO | ||||||||
| Todd Young | 477,096 | 0 | 2,175,000 | 725,004 | 0 | 0 | 1,377,789 | 4,754,889 |
| Former Executive Vice President and Chief Financial Officer | ||||||||
| Robert VanHimbergen | 317,308 | 890,000 | 2,285,026 | 550,002 | 539,550 | 0 | 79,419 | 4,661,304 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Ellen de Brabander | 847,829 | 0 | 1,716,010 | 572,003 | 739,307 | 0 | 36,081 | 3,911,229 |
| Executive Vice President, Innovation and Regulatory | ||||||||
| Ramiro Cabral | 650,000 | 0 | 1,500,011 | 500,003 | 566,800 | 0 | 26,952 | 3,243,767 |
| Executive Vice President, President International | ||||||||
| Timothy Bettington | 656,000 | 0 | 1,050,020 | 350,005 | 500,528 | 0 | 26,952 | 2,583,505 |
| Executive Vice President, Center for Strategic Growth | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jeffrey Simmons | $14,925,756 | $14,833,704 | $13,663,169 | ↑ +92,052 |
| Todd Young | 4,754,889 | 4,109,361 | 3,726,720 | ↑ +645,528 |
| Robert VanHimbergen | 4,661,304 | — | — | — |
| Ellen de Brabander | 3,911,229 | 3,913,932 | 3,683,732 | ↓ −2,703 |
| Ramiro Cabral | 3,243,767 | 2,942,471 | 2,650,754 | ↑ +301,296 |
| Timothy Bettington | 2,583,505 | 2,533,389 | 2,053,962 | ↑ +50,116 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Elanco Animal Health Inc's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ELAN reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Elanco Animal Health Inc Peer Teardown Report
$14,925,756 Jeffrey Simmons total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 6, 2026 · Source: 0001739104-26-000016 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for ELAN
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order ELAN
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses ELAN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ELAN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Elanco Animal Health Inc Executive Compensation Report
$1,500
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Ramiro Cabral | EVP | $3,243,767 |
| Jeffrey Simmons | CEO | $14,925,756 |
| Ellen de Brabander | EVP | $3,911,229 |
| Robert VanHimbergen | CFO | $4,661,304 |
| Timothy Bettington | EVP | $2,583,505 |
| Todd Young | CFO | $4,754,889 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Art Garcia | Independent Director | $330,007 |
| Craig Wallace | Independent Director | $122,649 |
| Deborah Kochevar | Independent Director | $346,007 |
| Denise Scots-Knight | Independent Director | $330,007 |
| John Bilbrey | Independent Director | $128,671 |
| Kapila Anand | Independent Director | $297,507 |
| Kathleen Turner | Independent Director | $122,649 |
| Kirk McDonald | Independent Director | $350,007 |
| Lawrence Kurzius | Chair of the Board | $480,007 |
| Michael Harrington | Independent Director | $346,007 |
| Paul Herendeen | Independent Director | $340,029 |
| R. David Hoover | Independent Director | $330,007 |
| Stacey Ma | Independent Director | $252,480 |
| William Doyle | Independent Director | $68,332 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-04-17 | — | 190 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Dividend-equivalent accruals | 2026-05-01 | — | 200 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Dividend-equivalent accruals | 2026-05-15 | — | 227 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Rajeev A. Modi | SEE REMARKS | 2026-05-15 | A | 4,911 | 20 | 99,939 | Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-05-15 | A | 4,971 | 20 | 99,843 | Common | Form 4 ↗ |
| Lawrence Kurzius | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Art Garcia | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kapila Anand | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Michael Harrington | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Michael Harrington | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| R. David Hoover | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Paul Herendeen | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Paul Herendeen | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kirk McDonald | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Denise Scots-Knight | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Denise Scots-Knight | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Stacey Ma | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence Kurzius | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kapila Anand | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Art Garcia | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Stacey Ma | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Deborah Kochevar | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kirk McDonald | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-05-29 | — | 189 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Dividend-equivalent accruals | 2026-06-12 | — | 186 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Dividend-equivalent accruals | 2026-06-26 | — | 183 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Kapila Anand | Director | 2026-06-30 | A | 584.11 | 25 | 14,375 | Derivative, Class A Common | Form 4 ↗ |
| David S. Kinard | SEE REMARKS | 2026-07-01 | A | 25,620 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-07-07 | D | 15,336 | 25 | 377,879 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-10 | — | 181 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Dividend-equivalent accruals | 2026-07-24 | — | 181 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Paul Herendeen | Director | 2026-08-07 | A | 10,000 | 24 | 236,850 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-07 | — | 203 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Robert VanHimbergen | EVP and CFO | 2026-08-07 | A | 4,200 | 23 | 96,926 | Common | Form 4 ↗ |
| Michael Harrington | Director | 2026-08-12 | A | 5,000 | 22 | 109,100 | Common | Form 4 ↗ |
| Shiv O'Neill | GC AND CORP SEC | 2026-08-18 | A | 3,998 | 24 | 94,273 | Common | Form 4 ↗ |
| Lawrence Kurzius | Director | 2026-08-20 | A | 40,000 | 23 | 935,920 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-08-21 | — | 188 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Dividend-equivalent accruals | 2026-09-04 | — | 184 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Dividend-equivalent accruals | 2026-09-18 | — | 201 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
| Kapila Anand | Director | 2026-09-30 | A | 642.03 | 22 | 14,375 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-02 | — | 203 | — | ~4,501 | 3 insiders, 3 accrual rows | ||
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Robert VanHimbergen | EVP and CFO | 2026-04-17 | A | 8.32 | $24 | $197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-04-17 | A | 62.37 | 24 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-04-17 | A | 119.38 | 24 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-05-01 | A | 125.59 | 23 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-05-01 | A | 8.75 | 23 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-05-01 | A | 65.61 | 23 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-05-15 | A | 142.34 | 20 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-05-15 | A | 74.37 | 20 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-05-15 | A | 4,911 | 20 | 99,939 | Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-05-15 | A | 9.92 | 20 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-05-15 | A | 4,971 | 20 | 99,843 | Common | Form 4 ↗ |
| Lawrence Kurzius | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Art Garcia | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kapila Anand | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Michael Harrington | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Michael Harrington | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| R. David Hoover | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Paul Herendeen | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Paul Herendeen | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kirk McDonald | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Denise Scots-Knight | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Denise Scots-Knight | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Stacey Ma | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Lawrence Kurzius | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kapila Anand | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Art Garcia | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Stacey Ma | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Deborah Kochevar | Director | 2026-05-21 | A | 4,678 | 0 | 0 | Common | Form 4 ↗ |
| Kirk McDonald | Director | 2026-05-21 | A | 12,196 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-05-29 | A | 118.53 | 24 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-05-29 | A | 61.93 | 24 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-05-29 | A | 8.26 | 24 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-06-12 | A | 116.96 | 24 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-06-12 | A | 8.15 | 24 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-06-12 | A | 61.11 | 24 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-06-26 | A | 8.02 | 25 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-06-26 | A | 115.06 | 25 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-06-26 | A | 60.11 | 25 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Kapila Anand | Director | 2026-06-30 | A | 584.11 | 25 | 14,375 | Derivative, Class A Common | Form 4 ↗ |
| David S. Kinard | SEE REMARKS | 2026-07-01 | A | 25,620 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-07-07 | D | 15,336 | 25 | 377,879 | Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-07-10 | A | 113.9 | 25 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-07-10 | A | 7.94 | 25 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-07-10 | A | 59.51 | 25 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-07-24 | A | 7.91 | 25 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-07-24 | A | 59.29 | 25 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-07-24 | A | 113.49 | 25 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Paul Herendeen | Director | 2026-08-07 | A | 10,000 | 24 | 236,850 | Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-08-07 | A | 66.77 | 22 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-08-07 | A | 8.91 | 22 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-08-07 | A | 127.8 | 22 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-08-07 | A | 4,200 | 23 | 96,926 | Common | Form 4 ↗ |
| Michael Harrington | Director | 2026-08-12 | A | 5,000 | 22 | 109,100 | Common | Form 4 ↗ |
| Shiv O'Neill | GC AND CORP SEC | 2026-08-18 | A | 3,998 | 24 | 94,273 | Common | Form 4 ↗ |
| Lawrence Kurzius | Director | 2026-08-20 | A | 40,000 | 23 | 935,920 | Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-08-21 | A | 117.94 | 24 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-08-21 | A | 8.22 | 24 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-08-21 | A | 61.62 | 24 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-09-04 | A | 115.38 | 25 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-09-04 | A | 60.28 | 25 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-09-04 | A | 8.04 | 25 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-09-18 | A | 8.79 | 22 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-09-18 | A | 65.88 | 22 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-09-18 | A | 126.09 | 22 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Kapila Anand | Director | 2026-09-30 | A | 642.03 | 22 | 14,375 | Derivative, Class A Common | Form 4 ↗ |
| Robert VanHimbergen | EVP and CFO | 2026-10-02 | A | 8.9 | 22 | 197 | Derivative, Class A Common | Form 4 ↗ |
| Rajeev A. Modi | SEE REMARKS | 2026-10-02 | A | 66.71 | 22 | 1,477 | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Simmons | Director | 2026-10-02 | A | 127.68 | 22 | 2,827 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Jeffrey Simmons | PSU | 2025-03-03 | — | 530,504 | — | 1,061,008 | $6,000,000 |
| Timothy Bettington | PSU | 2025-03-03 | — | 61,893 | — | 123,786 | 700,010 |
| Robert VanHimbergen | OTHER | 2025-10-01 | — | — | 8 | — | 550,002 |
| Todd Young | OPTION | 2025-03-03 | — | — | 134,509 | — | 725,004 |
| Ramiro Cabral | PSU | 2025-03-03 | — | 88,418 | — | 176,836 | 1,000,008 |
| Jeffrey Simmons | OPTION | 2025-03-03 | — | — | 556,587 | — | 3,000,004 |
| Jeffrey Simmons | RSU | 2025-03-03 | — | — | 265,252 | — | 3,000,000 |
| Ramiro Cabral | RSU | 2025-03-03 | — | — | 44,209 | — | 500,004 |
| Timothy Bettington | RSU | 2025-03-03 | — | — | 30,947 | — | 350,011 |
| Robert VanHimbergen | RSU | 2025-10-01 | — | — | 83,414 | — | 1,735,011 |
| Todd Young | RSU | 2025-03-03 | — | — | 64,103 | — | 725,005 |
| Timothy Bettington | OPTION | 2025-03-03 | — | — | 64,936 | — | 350,005 |
| Ramiro Cabral | OPTION | 2025-03-03 | — | — | 92,765 | — | 500,003 |
| Robert VanHimbergen | RSU | 2025-10-01 | — | — | 26,443 | — | 550,014 |
| Ellen de Brabander | RSU | 2025-03-03 | — | — | 50,575 | — | — |
| Ellen de Brabander | PSU | 2025-03-03 | — | 101,150 | — | 202,300 | 1,144,007 |
| Ellen de Brabander | OPTION | 2025-03-03 | — | — | 106,123 | — | 572,003 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Jeffrey Simmons | $3,000,000 | $6,000,000 | $3,000,004 | 50.0% |
| Timothy Bettington | 350,011 | 700,010 | 350,005 | 50.0% |
| Robert VanHimbergen | 2,285,025 | 0 | 0 | 0.0% |
| Todd Young | 725,005 | 0 | 725,004 | 0.0% |
| Ramiro Cabral | 500,004 | 1,000,008 | 500,003 | 50.0% |
| Ellen de Brabander | 0 | 1,144,007 | 572,003 | 66.7% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jeffrey Simmons | RSU | 125,391 | — | $2,837,598 |
| Ramiro Cabral | RSU | 44,209 | — | 1,000,450 |
| Timothy Bettington | RSU | 43,669 | — | 988,229 |
| Jeffrey Simmons | Option | 273,470 | 16.03 | — |
| Robert VanHimbergen | RSU | 26,443 | — | 598,405 |
| Robert VanHimbergen | RSU | 15,416 | — | 348,864 |
| Robert VanHimbergen | Option | 35,208 | 11.26 | — |
| Jeffrey Simmons | RSU | 374,299 | — | 8,470,386 |
| Jeffrey Simmons | RSU | 530,504 | — | 12,005,306 |
| Jeffrey Simmons | RSU | 265,252 | — | 6,002,653 |
| Robert VanHimbergen | RSU | 101,150 | — | 2,289,025 |
| Ramiro Cabral | RSU | 88,418 | — | 2,000,899 |
| Jeffrey Simmons | RSU | 84,548 | — | 1,913,321 |
| Robert VanHimbergen | RSU | 21,338 | — | 482,879 |
| Robert VanHimbergen | RSU | 83,414 | — | 1,887,659 |
| Robert VanHimbergen | RSU | 50,575 | — | 1,144,512 |
| Timothy Bettington | Option | 64,936 | 11.31 | — |
| Robert VanHimbergen | RSU | 63,694 | — | 1,441,395 |
| Timothy Bettington | RSU | 61,893 | — | 1,400,639 |
| Ramiro Cabral | RSU | 18,966 | — | 429,201 |
| Ramiro Cabral | RSU | 56,613 | — | 1,281,152 |
| Robert VanHimbergen | RSU | 34,154 | — | 772,905 |
| Timothy Bettington | RSU | 14,630 | — | 331,077 |
| Timothy Bettington | RSU | 30,947 | — | 700,331 |
| Ramiro Cabral | RSU | 12,835 | — | 290,456 |
| Jeffrey Simmons | Option | 193,104 | 11.26 | — |
| Jeffrey Simmons | Option | 556,587 | 11.31 | — |
| Robert VanHimbergen | Option | 53,869 | 20.8 | — |
| Robert VanHimbergen | Option | 46,536 | 16.03 | — |
| Robert VanHimbergen | Option | 106,123 | 11.31 | — |
| Ramiro Cabral | Option | 29,311 | 11.26 | — |
| Ramiro Cabral | Option | 41,363 | 16.03 | — |
| Ramiro Cabral | Option | 92,765 | 11.31 | — |
| Timothy Bettington | Option | 31,906 | 16.03 | — |
Elanco's compensation program is designed to attract and retain talented executives, align executive pay with company performance, and drive long-term shareholder value. The program responds to shareholder feedback by incorporating metrics like sales growth and relative TSR.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Willis Towers Watson |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 383,528,222 | 84,173,798 | 253,471 | 82% | Passed |
| 2025 | 2025-05-16 | 244,532,049 | 212,491,837 | 117,025 | 53.51% | Passed |
| 2024 | 2024-05-30 | 409,526,328 | 31,095,963 | 549,797 | 92.94% | Passed |
| 2023 | 2023-05-18 | 351,081,265 | 82,468,671 | 2,251,230 | 80.98% | Passed |
| 2022 | 2022-05-18 | 371,016,128 | 28,930,174 | 142,534 | 92.77% | Passed |
| 2021 | 2021-05-19 | 382,057,347 | 12,983,446 | 250,205 | 96.71% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-05-21 | 82%a |
| 2025 | 2025-05-16 | 53.51%b |
| 2024 | 2024-05-30 | 92.94%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions or broker non-votes with respect to these proposals, if any, will have no effect on the outcome of the vote.”.
c. Approved under the standard stated in the filing — “Abstentions or broker non-votes with respect to these proposals, if any, will have no effect on the outcome of the vote.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 181 : 1 |
|---|---|
| CEO total compensation | $14,925,756 |
| Median employee compensation | $82,675 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Lawrence KurziusIndependent · Board Chair | $240,000 | $240,007 | — | — | — | $480,007 |
| Kirk McDonaldIndependent · Compensation and Human Capital (Chair) · Innovation, Science and Technology | 110,000 | 240,007 | — | — | — | 350,007 |
| Deborah KochevarIndependent · Corporate Governance · Innovation, Science and Technology (Chair) | 106,000 | 240,007 | — | — | — | 346,007 |
| Michael HarringtonIndependent · Audit · Corporate Governance (Chair) · Finance, Strategy and Oversight | 106,000 | 240,007 | — | — | — | 346,007 |
| Paul HerendeenIndependent · Audit · Finance, Strategy and Oversight (Chair) | 100,022 | 240,007 | — | — | — | 340,029 |
| R. David HooverIndependent · Corporate Governance · Compensation and Human Capital | 90,000 | 240,007 | — | — | — | 330,007 |
| Denise Scots-KnightIndependent · Compensation and Human Capital · Innovation, Science and Technology | 90,000 | 240,007 | — | — | — | 330,007 |
| Art GarciaIndependent · Audit · Finance, Strategy and Oversight | 90,000 | 240,007 | — | — | — | 330,007 |
| Kapila AnandIndependent · Audit (Chair) · Corporate Governance | 57,500 | 240,007 | — | — | — | 297,507 |
| Stacey MaIndependent · Compensation and Human Capital · Innovation, Science and Technology | 12,473 | 240,007 | — | — | — | 252,480 |
| John BilbreyIndependent | 39,896 | 88,775 | — | — | — | 128,671 |
| Craig WallaceIndependent | 33,874 | 88,775 | — | — | — | 122,649 |
| Kathleen TurnerIndependent | 33,874 | 88,775 | — | — | — | 122,649 |
| William DoyleIndependent | 19,000 | 49,332 | — | — | — | 68,332 |
| Jeffrey SimmonsEmployee director · Finance, Strategy and Oversight | — | — | — | — | — | 0 |
| Annual cash retainer | $90,000 |
|---|---|
| Annual equity retainer | $240,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 16,000 |
| Stock ownership guideline | Our Corporate Governance Guidelines state that directors should hold meaningful equity ownership positions in Elanco and that our Board will consider from time-to-time equity ownership requirements for Non-Employee Directors. |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,128,639 |
| Equity awards (grant-date value) | $2,715,727 |
| All other compensation | $0 |
| Total cost of the board | $3,844,366 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Elanco Animal Health Inc names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Elanco Animal Health Inc.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Incyte Corporation | 2025 | William Meury | $647,260 | $27,509,657 | $2,573,998 | $1,300,000 | $32,085,952 |
| 2 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 3 | Vertex Pharmaceuticals, Inc. | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 4 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 5 | Zoetis Inc. | 2025 | Kristin Peck | 1,350,000 | 10,218,583 | 3,406,229 | 2,187,000 | 19,046,509 |
| 6 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 7 | Bausch Health Companies Inc. | 2025 | Thomas Appio | 1,236,000 | 13,032,562 | 0 | 2,336,000 | 16,877,326 |
| 8 | Zimmer Biomet Holdings, Inc. | 2025 | Ivan Tornos | 1,281,846 | 12,000,101 | 0 | 2,420,767 | 16,106,550 |
| 9 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 10 | Charles River Laboratories International, Inc. | 2025 | James Foster | 1,545,636 | 11,601,089 | 0 | 2,182,666 | 15,435,220 |
| 11 | Elanco Animal Health Inc | 2025 | Jeffrey Simmons | 1,200,000 | 9,000,000 | 3,000,004 | 1,700,400 | 14,925,756 |
| 12 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 13 | Revvity, Inc. | 2025 | Prahlad R. Singh | 1,129,231 | 7,694,985 | 2,559,152 | 2,385,450 | 13,809,549 |
| 14 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 15 | STERIS plc | 2026 | Daniel Carestio | 1,095,707 | 4,333,951 | 4,334,251 | 1,725,007 | 11,508,522 |
| 16 | QuidelOrtho Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 17 | Perrigo Company plc | 2025 | Patrick Lockwood-Taylor | 1,223,333 | 6,990,564 | 0 | 687,250 | 9,042,603 |
| 18 | DENTSPLY SIRONA Inc. | 2025 | Daniel Scavilla | 431,753 | 3,484,488 | 3,221,523 | 437,150 | 8,760,139 |
| 19 | Catalent, Inc. | 2023 | Alessandro Maselli | 925,000 | 3,850,216 | 1,650,019 | 0 | 6,583,672 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Elanco Animal Health Inc | not disclosed | not disclosed | No | Willis Towers Watson |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Bausch Health Companies Inc. | 126% | PSU 60 · RSU 40 | Yes — Relative Total Shareholder Return (rTSR) | Pay Governance |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| Catalent, Inc. | not disclosed | PSU 50 · Option 30 · RSU 20 | not disclosed | Frederic W. Cook & Co., Inc. |
| Charles River Laboratories International, Inc. | 139% | PSU 60 · RSU 40 | Yes — Three-year rTSR | Pay Governance |
| DENTSPLY SIRONA Inc. | 66% | PSU 50 · Options 50 | No | Frederic W. Cook & Co., Inc. |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Perrigo Company plc | 44.3% | PSU 70 · RSU 30 | Yes — Relative TSR (rTSR) | FW Cook |
| QuidelOrtho Corporation | 127% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| Revvity, Inc. | 124% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| STERIS plc | 125.1% | RSU 50 · Options 50 | not disclosed | Frederic W. Cook & Co., Inc. |
| Vertex Pharmaceuticals, Inc. | not disclosed | PSU 55 · RSU 45 | No | not disclosed |
| Zimmer Biomet Holdings, Inc. | 125.9% | RSU 50 · PSU 50 | Yes — Relative TSR | Semler Brossy |
| Zoetis Inc. | 108% | PSU 50 · Options 25 · RSU 25 | Yes — Relative TSR | Pearl Meyer |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Jeffrey Simmons | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation”. As printed: 14,925,756. Filing ↗machine: r4 · c24 · span 1067844–1067854 |
| 2 | Section 01, Todd Young | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation”. As printed: 4,754,889. Filing ↗machine: r27 · c24 · span 1111204–1111213 |
| 3 | Section 01, Robert VanHimbergen | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation”. As printed: 4,661,304. Filing ↗machine: r9 · c24 · span 1077803–1077812 |
| 4 | Section 01, Ellen de Brabander | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation”. As printed: 3,911,229. Filing ↗machine: r12 · c24 · span 1082147–1082156 |
| 5 | Section 01, Ramiro Cabral | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation”. As printed: 3,243,767. Filing ↗machine: r17 · c24 · span 1091930–1091939 |
| 6 | Section 01, Timothy Bettington | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation”. As printed: 2,583,505. Filing ↗machine: r22 · c24 · span 1101906–1101915 |
| 7 | Section 03, Jeffrey Simmons PSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r7 · c16 · span 1162921–1162930 |
| 8 | Section 03, Timothy Bettington PSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r31 · c16 · span 1210091–1210098 |
| 9 | Section 03, Robert VanHimbergen OTHER | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r15 · c14 · span 1179247–1179254 |
| 10 | Section 03, Todd Young OPTION | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r39 · c13 · span 1226039–1226046 |
| 11 | Section 03, Ramiro Cabral PSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r25 · c16 · span 1198239–1198248 |
| 12 | Section 03, Jeffrey Simmons OPTION | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r9 · c14 · span 1167934–1167943 |
| 13 | Section 03, Jeffrey Simmons RSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r8 · c14 · span 1165333–1165342 |
| 14 | Section 03, Ramiro Cabral RSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r26 · c14 · span 1200650–1200657 |
| 15 | Section 03, Timothy Bettington RSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r32 · c14 · span 1212500–1212507 |
| 16 | Section 03, Robert VanHimbergen RSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r13 · c14 · span 1174316–1174325 |
| 17 | Section 03, Todd Young RSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r38 · c13 · span 1223502–1223509 |
| 18 | Section 03, Timothy Bettington OPTION | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r33 · c15 · span 1215206–1215213 |
| 19 | Section 03, Ramiro Cabral OPTION | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r27 · c14 · span 1203285–1203292 |
| 20 | Section 03, Robert VanHimbergen RSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t200 · r14 · c13 · span 1176750–1176757 |
| 21 | Section 03, Ellen de Brabander RSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1188155–1188161 |
| 22 | Section 03, Ellen de Brabander PSU | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1186243–1186252 |
| 23 | Section 03, Ellen de Brabander OPTION | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 24 | Section 07, pay ratio | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “CEO Pay Ratio”. As printed: 181 : 1. Filing ↗ |
| 25 | Section 08, Lawrence Kurzius | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 480,007. Filing ↗machine: span 621318–621572 |
| 26 | Section 08, Kirk McDonald | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 350,007. Filing ↗machine: span 624161–624415 |
| 27 | Section 08, Deborah Kochevar | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 346,007. Filing ↗machine: span 619891–620145 |
| 28 | Section 08, Michael Harrington | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 346,007. Filing ↗machine: span 615617–615871 |
| 29 | Section 08, Paul Herendeen | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 340,029. Filing ↗machine: span 617042–617296 |
| 30 | Section 08, R. David Hoover | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 330,007. Filing ↗machine: span 618464–618718 |
| 31 | Section 08, Denise Scots-Knight | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 330,007. Filing ↗machine: span 625590–625844 |
| 32 | Section 08, Art Garcia | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 330,007. Filing ↗machine: span 614188–614442 |
| 33 | Section 08, Kapila Anand | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 297,507. Filing ↗machine: span 609502–609756 |
| 34 | Section 08, Stacey Ma | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 252,480. Filing ↗machine: span 622737–622991 |
| 35 | Section 08, John Bilbrey | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 128,671. Filing ↗machine: span 611135–611389 |
| 36 | Section 08, Craig Wallace | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 122,649. Filing ↗machine: span 629020–629306 |
| 37 | Section 08, Kathleen Turner | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 122,649. Filing ↗machine: span 627226–627480 |
| 38 | Section 08, William Doyle | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 68,332. Filing ↗machine: span 612769–613022 |
| 39 | Section 08, Jeffrey Simmons | DEF 14A | 2026-04-08 | 0001739104-26-000016 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 40 | Section 02, Robert VanHimbergen 2026-04-17 | Form 4 | 2026-04-21 | 0001724169-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Rajeev A. Modi 2026-04-17 | Form 4 | 2026-04-21 | 0001916473-26-000020 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Jeffrey Simmons 2026-04-17 | Form 4 | 2026-04-21 | 0001479079-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Jeffrey Simmons 2026-05-01 | Form 4 | 2026-05-05 | 0001479079-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Robert VanHimbergen 2026-05-01 | Form 4 | 2026-05-05 | 0001724169-26-000021 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Rajeev A. Modi 2026-05-01 | Form 4 | 2026-05-05 | 0001916473-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Jeffrey Simmons 2026-05-15 | Form 4 | 2026-05-19 | 0001479079-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Rajeev A. Modi 2026-05-15 | Form 4 | 2026-05-19 | 0001916473-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Rajeev A. Modi 2026-05-15 | Form 4 | 2026-05-19 | 0001916473-26-000024 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Robert VanHimbergen 2026-05-15 | Form 4 | 2026-05-19 | 0001724169-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Jeffrey Simmons 2026-05-15 | Form 4 | 2026-05-19 | 0001479079-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Lawrence Kurzius 2026-05-21 | Form 4 | 2026-05-26 | 0001352090-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Art Garcia 2026-05-21 | Form 4 | 2026-05-26 | 0001183585-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Kapila Anand 2026-05-21 | Form 4 | 2026-05-26 | 0001679166-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Michael Harrington 2026-05-21 | Form 4 | 2026-05-26 | 0001566340-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Michael Harrington 2026-05-21 | Form 4 | 2026-05-26 | 0001566340-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, R. David Hoover 2026-05-21 | Form 4 | 2026-05-26 | 0001186033-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Paul Herendeen 2026-05-21 | Form 4 | 2026-05-26 | 0001374175-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Paul Herendeen 2026-05-21 | Form 4 | 2026-05-26 | 0001374175-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Kirk McDonald 2026-05-21 | Form 4 | 2026-05-26 | 0001517740-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Denise Scots-Knight 2026-05-21 | Form 4 | 2026-05-26 | 0001297000-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Denise Scots-Knight 2026-05-21 | Form 4 | 2026-05-26 | 0001297000-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Stacey Ma 2026-05-21 | Form 4 | 2026-05-26 | 0001872431-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Lawrence Kurzius 2026-05-21 | Form 4 | 2026-05-26 | 0001352090-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Kapila Anand 2026-05-21 | Form 4 | 2026-05-26 | 0001679166-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Art Garcia 2026-05-21 | Form 4 | 2026-05-26 | 0001183585-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Stacey Ma 2026-05-21 | Form 4 | 2026-05-26 | 0001872431-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Deborah Kochevar 2026-05-21 | Form 4 | 2026-05-26 | 0001448579-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Kirk McDonald 2026-05-21 | Form 4 | 2026-05-26 | 0001517740-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Jeffrey Simmons 2026-05-29 | Form 4 | 2026-06-02 | 0001479079-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Rajeev A. Modi 2026-05-29 | Form 4 | 2026-06-02 | 0001916473-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Robert VanHimbergen 2026-05-29 | Form 4 | 2026-06-02 | 0001724169-26-000025 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Jeffrey Simmons 2026-06-12 | Form 4 | 2026-06-16 | 0001479079-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Robert VanHimbergen 2026-06-12 | Form 4 | 2026-06-16 | 0001724169-26-000027 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Rajeev A. Modi 2026-06-12 | Form 4 | 2026-06-16 | 0001916473-26-000028 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Robert VanHimbergen 2026-06-26 | Form 4 | 2026-06-30 | 0001724169-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Jeffrey Simmons 2026-06-26 | Form 4 | 2026-06-30 | 0001479079-26-000031 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Rajeev A. Modi 2026-06-26 | Form 4 | 2026-06-30 | 0001916473-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Kapila Anand 2026-06-30 | Form 4 | 2026-07-02 | 0001679166-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, David S. Kinard 2026-07-01 | Form 4 | 2026-07-02 | 0001752439-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Robert VanHimbergen 2026-07-07 | Form 4 | 2026-07-09 | 0001724169-26-000031 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Jeffrey Simmons 2026-07-10 | Form 4 | 2026-07-14 | 0001479079-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Robert VanHimbergen 2026-07-10 | Form 4 | 2026-07-14 | 0001724169-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Rajeev A. Modi 2026-07-10 | Form 4 | 2026-07-14 | 0001916473-26-000032 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Robert VanHimbergen 2026-07-24 | Form 4 | 2026-07-28 | 0001724169-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Rajeev A. Modi 2026-07-24 | Form 4 | 2026-07-28 | 0001916473-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Jeffrey Simmons 2026-07-24 | Form 4 | 2026-07-28 | 0001479079-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Paul Herendeen 2026-08-07 | Form 4 | 2026-08-10 | 0001374175-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Rajeev A. Modi 2026-08-07 | Form 4 | 2026-08-10 | 0001916473-26-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Robert VanHimbergen 2026-08-07 | Form 4 | 2026-08-10 | 0001724169-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Jeffrey Simmons 2026-08-07 | Form 4 | 2026-08-10 | 0001479079-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Robert VanHimbergen 2026-08-07 | Form 4 | 2026-08-10 | 0001724169-26-000037 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Michael Harrington 2026-08-12 | Form 4 | 2026-08-13 | 0001566340-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Shiv O'Neill 2026-08-18 | Form 4 | 2026-08-18 | 0002001171-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Lawrence Kurzius 2026-08-20 | Form 4 | 2026-08-21 | 0001352090-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Jeffrey Simmons 2026-08-21 | Form 4 | 2026-08-25 | 0001479079-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Robert VanHimbergen 2026-08-21 | Form 4 | 2026-08-25 | 0001724169-26-000039 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Rajeev A. Modi 2026-08-21 | Form 4 | 2026-08-25 | 0001916473-26-000038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Jeffrey Simmons 2026-09-04 | Form 4 | 2026-09-09 | 0001479079-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Rajeev A. Modi 2026-09-04 | Form 4 | 2026-09-09 | 0001916473-26-000040 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Robert VanHimbergen 2026-09-04 | Form 4 | 2026-09-09 | 0001724169-26-000041 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Robert VanHimbergen 2026-09-18 | Form 4 | 2026-09-22 | 0001724169-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Rajeev A. Modi 2026-09-18 | Form 4 | 2026-09-22 | 0001916473-26-000042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Jeffrey Simmons 2026-09-18 | Form 4 | 2026-09-22 | 0001479079-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Kapila Anand 2026-09-30 | Form 4 | 2026-10-01 | 0001679166-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Robert VanHimbergen 2026-10-02 | Form 4 | 2026-10-06 | 0001724169-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Rajeev A. Modi 2026-10-02 | Form 4 | 2026-10-06 | 0001916473-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Jeffrey Simmons 2026-10-02 | Form 4 | 2026-10-06 | 0001479079-26-000045 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 06, 2026 vote | Form 8-K | 2026-05-27 | 0001104659-26-067002 | Item 5.07 · say-on-pay result. As reported: 82% (votes for as printed: 383,528,222). Filing ↗ |
| 109 | Section 06, 2025 vote | Form 8-K | 2025-05-21 | 0001104659-25-051136 | Item 5.07 · say-on-pay result. As reported: 53.51% (votes for as printed: 244,532,049). Filing ↗ |
| 110 | Section 06, 2024 vote | Form 8-K | 2024-06-04 | 0001104659-24-068253 | Item 5.07 · say-on-pay result. As reported: 92.94% (votes for as printed: 409,526,328). Filing ↗ |
| 111 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 112 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 113 | Section 09b board cost (computed) | Computed | — | — | Cash 1,128,639 + equity 2,715,727 + all other 0 = 3,844,366, summed across the director compensation table rows.machine: formula: Σ = 3,844,366 |
| 114 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 115 | Biogen Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187303 | CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. Filing ↗machine: r2 · c16 · span 1174380–1174391 |
| 116 | Vertex Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-02 | 0000875320-26-000153 | CEO total compensation as printed in Vertex Pharmaceuticals, Inc.'s own proxy. As printed: 21,144,261. Filing ↗machine: r2 · c13 · span 2942799–2942809 |
| 117 | Jazz Pharmaceuticals plc, Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 118 | Zoetis Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001555280-26-000015 | CEO total compensation as printed in Zoetis Inc.'s own proxy. As printed: 19,046,509. Filing ↗machine: r3 · c24 · span 1448788–1448798 |
| 119 | Edwards Lifesciences Corporation, Section 10b CEO total | DEF 14A | 2026-03-26 | 0001099800-26-000015 | CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 120 | Bausch Health Companies Inc., Section 10b CEO total | DEF 14A | 2026-04-08 | 0001140361-26-013816 | CEO total compensation as printed in Bausch Health Companies Inc.'s own proxy. As printed: 16,877,326. Filing ↗machine: r2 · c25 · span 1071578–1071588 |
| 121 | Zimmer Biomet Holdings, Inc., Section 10b CEO total | DEF 14A | 2026-04-01 | 0001193125-26-135661 | CEO total compensation as printed in Zimmer Biomet Holdings, Inc.'s own proxy. As printed: 16,106,550. Filing ↗machine: t111 · r3 · c16 · span 1895785–1895795 |
| 122 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 123 | Charles River Laboratories International, Inc., Section 10b CEO total | DEF 14A | 2026-03-31 | 0001104659-26-037367 | CEO total compensation as printed in Charles River Laboratories International, Inc.'s own proxy. As printed: 15,435,220. Filing ↗machine: r1 · c53 · span 1119658–1119668 |
| 124 | Elanco Animal Health Inc (subject), Section 10b CEO total | DEF 14A | 2026-04-08 | 0001739104-26-000016 | CEO total compensation as printed in Elanco Animal Health Inc's own proxy. As printed: 14,925,756. Filing ↗machine: r4 · c24 · span 1067844–1067854 |
| 125 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 126 | Revvity, Inc., Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-107266 | CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: r3 · c39 · span 751285–751295 |
| 127 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 128 | STERIS plc, Section 10b CEO total | DEF 14A | 2026-06-11 | 0001193125-26-267599 | CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600 |
| 129 | QuidelOrtho Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001906324-26-000018 | CEO total compensation as printed in QuidelOrtho Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622 |
| 130 | Perrigo Company plc, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001585364-26-000024 | CEO total compensation as printed in Perrigo Company plc's own proxy. As printed: 9,042,603. Filing ↗machine: r3 · c12 · span 2143273–2143282 |
| 131 | DENTSPLY SIRONA Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0000818479-26-000125 | CEO total compensation as printed in DENTSPLY SIRONA Inc.'s own proxy. As printed: 8,760,139. Filing ↗machine: r5 · c27 · span 1201378–1201387 |
| 132 | Catalent, Inc., Section 10b CEO total | DEF 14A | 2023-12-15 | 0001193125-23-295996 | CEO total compensation as printed in Catalent, Inc.'s own proxy. As printed: 6,583,672. Filing ↗machine: r3 · c31 · span 1055835–1055844 |
| 133 | Section 10a, Bausch Health Companies Inc. reciprocity | DEF 14A | — | 0001140361-26-013816 | Bausch Health Companies Inc. names Elanco Animal Health Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 134 | Section 10a, Zimmer Biomet Holdings, Inc. reciprocity | DEF 14A | — | 0001193125-26-135661 | Zimmer Biomet Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 135 | Section 10a, Vertex Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000875320-26-000153 | Vertex Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 136 | Section 10a, Edwards Lifesciences Corporation reciprocity | DEF 14A | — | 0001099800-26-000015 | Edwards Lifesciences Corporation's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 137 | Section 10a, QuidelOrtho Corporation reciprocity | DEF 14A | — | 0001906324-26-000018 | QuidelOrtho Corporation's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 138 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 139 | Section 10a, Revvity, Inc. reciprocity | DEF 14A | — | 0001193125-26-107266 | Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 140 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc. names Elanco Animal Health Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 141 | Section 10a, Catalent, Inc. reciprocity | DEF 14A | — | 0001193125-23-295996 | Catalent, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 142 | Section 10a, Charles River Laboratories International, Inc. reciprocity | DEF 14A | — | 0001104659-26-037367 | Charles River Laboratories International, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 143 | Section 10a, Jazz Pharmaceuticals plc reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals plc's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 144 | Section 10a, DENTSPLY SIRONA Inc. reciprocity | DEF 14A | — | 0000818479-26-000125 | DENTSPLY SIRONA Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 145 | Section 10a, Perrigo Company plc reciprocity | DEF 14A | — | 0001585364-26-000024 | Perrigo Company plc's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 146 | Section 10a, Zoetis Inc. reciprocity | DEF 14A | — | 0001555280-26-000015 | Zoetis Inc. names Elanco Animal Health Inc in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 147 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
| 148 | Section 10a, STERIS plc reciprocity | DEF 14A | — | 0001193125-26-267599 | STERIS plc's most recent proxy was read; its disclosed peer group does not include Elanco Animal Health Inc. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Elanco Animal Health Inc Executive Compensation Report
$1,500